COMMUNIQUÉS West-GlobeNewswire

Clearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

06/09/2024 - 13:55

Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“ [...]

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06/09/2024 - 13:30

PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that [...]

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

06/09/2024 - 13:30

Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the [...]

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

06/09/2024 - 13:30

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]

Cartesian Therapeutics Announces New Employment Inducement Grant

06/09/2024 - 13:05

GAITHERSBURG, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune [...]

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

06/09/2024 - 13:00

SAN FRANCISCO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer [...]

Tonix Pharmaceuticals Launches National Awareness Campaign on the Impact of Gastroparesis or Stomach Paralysis on the Absorption of Oral Migraine Medications at PAINWeek

06/09/2024 - 13:00

Gastroparesis slows the ability of the stomach to empty into the small intestine and thereby can delay absorption of oral medications into the bloodstream Non-oral medications including nasal and injectables can bypass [...]

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

06/09/2024 - 13:00

MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

06/09/2024 - 13:00

- Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living with Duchenne - - Announced in celebration of World Duchenne [...]

Krystal Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference

06/09/2024 - 13:00

PITTSBURGH, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the H.C. Wainwright [...]

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

06/09/2024 - 13:00

ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, announced that it [...]

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

06/09/2024 - 13:00

Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell- [...]

BioConnection appoints Richard Sewalt as New Chief Commercial Officer

06/09/2024 - 09:43

OSS, The Netherlands – 6 September 2024, BioConnection , a leading Dutch contract development and manufacturing organization (CDMO) in the pharmaceutical industry, today announced the appointment of Richard Sewalt as [...]

Major shareholder announcement

06/09/2024 - 08:51

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]

BioCryst Presents New ORLADEYO® (berotralstat) Data at 7th Bradykinin Symposium

06/09/2024 - 08:00

RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the presentation of six posters, including the first interim real-word evidence from the [...]

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

06/09/2024 - 07:15

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of [...]

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

06/09/2024 - 02:43

Top-line data from VEGA-3 Phase 3 trial expected in first half of 2025 Top-line data from LYNX-2 Phase 3 trial in patients with decreased visual acuity under low light conditions following keratorefractive surgery [...]

Atsena Therapeutics Announces 12-Month Safety and Efficacy Data from Phase I/II Clinical Trial of ATSN-101 in LCA1 Published in The Lancet

06/09/2024 - 00:30

First time patients with LCA1 have been treated with gene therapy ATSN-101 demonstrated durable, clinically significant improvements in vision at the high dose and was well-tolerated 12 months post-treatment in patients [...]

NeuroOne® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

06/09/2024 - 00:23

EDEN PRAIRIE, Minn., Sept. 05, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and [...]